Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Wells Fargo Downgrades Verona Pharma to Equal-Weight, Lowers Price Target to $107

Author: Benzinga Newsdesk | July 10, 2025 07:32am
Wells Fargo analyst Tiago Fauth downgrades Verona Pharma (NASDAQ:VRNA) from Overweight to Equal-Weight and lowers the price target from $138 to $107.

Posted In: VRNA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist